MidLantic Urology
Welcome,         Profile    Billing    Logout  
 3 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moreno, Jose C
ACTIV-4, NCT04505774 / 2020-004285-19: Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Active, not recruiting
4
3239
Europe, US, RoW
theraputic heparin, unfractionated heparin, Enoxaparin, Dalteparin, Tinzaparin, Heparin, prophylactic heparin, enoxaparin, dalteparin, Fondparinux, P2Y12, Ticagrelor, Prasugrel, Clopidogrel, Crizanlizumab Injection, SGLT2 inhibitor, dapagliflozin, empagliflozin, canagliflozin, ertugliflozin
Matthew Neal MD, National Heart, Lung, and Blood Institute (NHLBI)
Covid19
08/23
06/24
NCT04740671 / 2020-005364-57: A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Active, not recruiting
3
388
Europe, US, RoW
HLX04-O, ranibizumab
Shanghai Henlius Biotech
Age Related Macular Degeneration
12/24
03/25
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/25
03/26
NCT05531565 / 2020-000727-40: A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
BIIB059 (litifilimab), litifilimab, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Active, not recruiting
2
532
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
07/24
08/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE

Recruiting
2
532
Europe, Japan, US, RoW
M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA
Systemic Lupus Erythematosus
04/25
04/25
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy

Recruiting
2
138
Europe, Japan, US
TAK-341, MEDI1341, Placebo
Takeda, AstraZeneca
Multiple System Atrophy
08/25
08/25
NCT05032196: Study of WVE-003 in Patients With Huntington's Disease

Recruiting
1/2
54
Europe, Canada, RoW
WVE-003
Wave Life Sciences Ltd.
Huntington Disease
12/24
12/24
CHARTER, NCT05437679: Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

Terminated
N/A
9
US
Blood collection, Data collection
Angle plc, MidLantic Urology, LLC
High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
08/23
08/23
E²-RADIatE, NCT03818503: E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

Recruiting
N/A
2000
Europe, RoW
European Organisation for Research and Treatment of Cancer - EORTC
Cancer
04/26
04/26
Zinar, Cheryl
NCT05799248: Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

Recruiting
3
113
US
rhPSMA-7.3 (18F), radiohybrid PSMA-targeted PET imaging agent, Radioligand for PET CT scanning
MidLantic Urology, Blue Earth Diagnostics
Prostate Cancer
05/24
05/24
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting
2
125
Canada, US
Ruvidar® (TLD-1433) Bladder infusion and PDT
Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
06/25
12/25
PRL-02-1001, NCT04729114: Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Recruiting
1/2
100
US
PRL-02 injection, prednisone, dexamethasone, docetaxel infusion
Astellas Pharma Global Development, Inc.
Prostate Cancer, mCRPC, mCSPC
12/24
04/25
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy

Active, not recruiting
N/A
196
US
Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy
Applaud Medical, Inc.
Urinary Stones
06/23
08/24
CHARTER, NCT05437679: Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

Terminated
N/A
9
US
Blood collection, Data collection
Angle plc, MidLantic Urology, LLC
High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
08/23
08/23
NCT05250908: INTIBIA Pivotal Study

Recruiting
N/A
225
Europe, US
INTIBIA Therapeutic, INTIBIA Non-Therapeutic
Coloplast A/S
Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations
03/24
03/25

Download Options